Single-Cell Omics Global Market Report 2024

The single-cell omics market size has grown rapidly in recent years. It will grow from $1.81 billion in 2023 to $2.1 billion in 2024 at a compound annual growth rate (CAGR) of 16.3%. The growth observed in the historic period within the field of single-cell omics can be attributed to several key factors. These include the discovery and understanding of cellular heterogeneity, advancements in the development and emergence of tools for single-cell analysis, progress in biomedical research, in-depth characterization of the immune system at the single-cell level, and the increasing prominence of precision medicine approaches. These factors collectively contributed to the growth and expansion of single-cell omics during the historic period by fostering a deeper comprehension of cellular diversity, providing innovative tools for analyzing individual cells, furthering biomedical research endeavors, enabling comprehensive insights into the immune system, and promoting the evolution of personalized approaches in medical treatments through precision medicine.

The single-cell omics market size is expected to see rapid growth in the next few years. It will grow to $3.84 billion in 2028 at a compound annual growth rate (CAGR) of 16.2%. Anticipated growth in the forecast period is expected due to increased adoption of single-cell omics in clinical diagnostics, its integration into multi-omics approaches, and its application in areas such as regenerative medicine, drug development, cellular therapies, and immunotherapies. Key trends projected for this period involve the rise of in vivo single-cell studies, the expanded use of single-cell omics in infectious disease research, advancements in microfluidics and single-cell sorting technologies, the integration of multiple omics data at the single-cell level, and the development of spatial single-cell profiling techniques. These trends are expected to shape the landscape of the industry and drive its growth in the coming forecasted period.

The anticipated rise in the prevalence of cancer is expected to significantly contribute to the growth of the single-cell omics market. Cancer, encompassing a range of illnesses characterized by uncontrolled cell proliferation and invasion, is a crucial focus for single-cell omics applications. The utilization of single-cell omics data plays a pivotal role in identifying biomarkers for cancer diagnosis, predicting prognosis, and discovering novel therapeutic targets within predetermined clinical cohorts. In 2023, the American Cancer Society Inc. reported that the expected number of new cancer cases in the United States is 1.9 million, marking an increase compared to the 1.8 million new cancer cases diagnosed in 2020. This rising prevalence of cancer serves as a driving force behind the growth of the single-cell omics market.

The increasing number of clinical trials is also expected to propel the growth of the single-cell omics market. Clinical trials, essential research studies conducted on human subjects to evaluate the safety and efficacy of medical interventions, treatments, or drugs, have seen a substantial surge. The application of single-cell omics in clinical trials facilitates detailed analyses of individual cells, offering valuable insights into cellular heterogeneity and enhancing precision medicine approaches. As of May 17, 2023, Xtalks reported that there are 452,604 registered clinical trials globally on ClinicalTrials.gov, representing a significant increase from the over 365,000 registered trials reported in early 2021. This surge in clinical trials serves as a driving factor for the growth of the single-cell omics market.

Product innovation stands out as a pivotal trend gaining traction in the single-cell omics market, with major companies actively pursuing the development of cutting-edge products to maintain their market positions. A notable example is Deepcell, a US-based software provider specializing in single-cell dimensional morphology analysis, which, in May 2023, introduced the REM-I Platform. This platform represents a scalable solution for single-cell imaging, high-dimensional analysis, and cell sorting, providing unprecedented insights into cell biology. The REM-I Platform is poised to catalyze new discoveries across various domains, including cancer biology, developmental biology, stem cell biology, gene therapy, and functional screening. Its unique combination of single-cell imaging, sorting, and high-dimensional analysis is expected to open new avenues for exploration and research.

Major companies in the single-cell omics market are concentrating on the development of advanced kits tailored for single-cell applications to drive market revenues. Sequencing kits, pre-packaged sets of reagents and materials designed for genetic sequencing processes, play a crucial role in streamlining laboratory workflows. Singular Genomics Systems, Inc., a US-based company specializing in novel next-generation sequencing, exemplifies this trend. In February 2023, the company launched the Max Read Kits for single-cell sequencing on the G4 Sequencing Platform. These kits, compatible with popular 10x Genomics assays, offer flexibility for sequencing 4 to 16 samples per run. The Max Read Kits deliver 800 million reads per flow cell with 80% to 90% Q30 quality. Singular Genomics has also elevated the quality specifications of the G4 Sequencing Platform's F2 and F3 flow cells, achieving up to 1.8 billion reads per run on the F3 flow cells for select applications. This strategic focus on advanced sequencing kits aligns with the industry's commitment to enhancing efficiency and precision in single-cell omics applications.

In March 2022, Singleron Biotechnologies, a genomics company based in China, successfully acquired Proteona Pte. Ltd for an undisclosed sum. This strategic acquisition was driven by Singleron's objective to extend its global footprint and gain access to Proteona's cutting-edge technologies specialized in single-cell multi-omic analysis. Proteona, headquartered in Singapore, is a precision medicine firm recognized for its proficiency in single-cell proteogenomic analysis.

Major companies operating in the single-cell omics market report are Danaher Corporation, Merck KGaA, Becton Dickinson and Company, GE HealthCare Technologies Inc., Thermo Fischer Scientific Inc., Agilent Technologies Inc., Sartorius AG, Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V, DiaSorin S.p.A., Tecan Group Ltd., BGI Genomics Co. Ltd., Promega Corporation, 10x Genomics Inc., Takara Bio Inc., NanoString Technologies Inc., Vizgen, HiFiBiO Therapeutics, Deepcell, Immunai, Mission Bio Inc., Standard BioTools Inc., CYTENA GmbH, Celsius Therapeutics, Scailyte AG, Single Cell Discoveries, ImmunoScape Pte. Ltd., Nodexus Inc., 1CellBio Inc.

North America was the largest region in the single-cell omics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single-cell omics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the single-cell omics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary types of single-cell omics products encompass single-cell genomics, single-cell transcriptomics, single-cell proteomics, and single-cell metabolomics. Single-cell genomics, for instance, is an advanced technique used to classify individual cells, identifying unique cell types and characterizing distinct cellular features. Various technologies are employed in single-cell omics, including cell isolation and sample preparation methods, as well as next-generation sequencing analysis. These technologies find application across diverse fields such as oncology, cell biology, neurology, immunology, and others. End users of single-cell omics products include pharmaceutical and biotechnology companies, academic and research institutions, hospital and diagnostic laboratories, and other relevant entities involved in advancing scientific research and medical applications.

The single-cell omics market research report is one of a series of new reports that provides single-cell omics market statistics, including single-cell omics industry global market size, regional shares, competitors with a single-cell omics market share, detailed single-cell omics market segments, market trends and opportunities, and any further data you may need to thrive in the single-cell omics industry. This single-cell omics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The single-cell omics market includes revenues earned by entities through single-cell sorting and isolation, single-cell sample preparation kits, and related single-cell data analysis software. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.